Favipiravir
Favipiravir (T-705), a guanine analogue, effectively inhibits the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, adding a recent study, reported its activity against 2019-nCoV [10]. Patients with 2019-nCoV are being recruited in randomized trials to evaluate the efficacy of favipiravir plus interferon-α (ChiCTR2000029600) and favipiravir plus baloxavirmarboxil (an approved influenza inhibitor targeting the cap-dependent endonuclease) (ChiCTR2000029544) [13]. Although, EC50 value of Favipiravir in Vero E6 cells was as high as 67 μM. It wasreported to reduce viral infection of 2019-nCoV in (EC50 = 61.88 μM, CC50 > 400 μM, SI > 6.46) concentrations [14] suggesting further in vivo studies to be screened against 2019-nCoV to test the efficacy of this antiviral nucleoside.